{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-085976","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2025-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.288530+00:00","generated_at":"2026-05-17T08:43:17.770347+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"United Therapeutics' Tyvaso succeeds in TETON-2 IPF study, shows 95.6mL FVC improvement","bullets":["TETON-2 met primary endpoint: Tyvaso improved absolute FVC by 95.6 mL vs placebo at week 52 (p<0.0001).","Statistically significant improvements in secondary endpoints including time to first clinical worsening, K-BILD, and DLCO.","Safety profile consistent with prior Tyvaso studies; no new safety signals observed.","Company plans FDA meeting to discuss expedited review; TETON-1 data expected H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-085976","json":"https://secwatch.observer/filing/0001104659-25-085976.json","markdown":"https://secwatch.observer/filing/0001104659-25-085976.md","text":"https://secwatch.observer/filing/0001104659-25-085976.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000110465925085976/0001104659-25-085976-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000110465925085976/tm2524831d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:43:17.770347+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}